Graft Patency of No-Touch Saphenous Veins Used as Aortocoronary Bypass Grafts.
Coronary artery bypass grafting
Saphenous vein
Journal
Journal of chest surgery
ISSN: 2765-1606
Titre abrégé: J Chest Surg
Pays: Korea (South)
ID NLM: 101775790
Informations de publication
Date de publication:
05 Sep 2023
05 Sep 2023
Historique:
received:
22
02
2023
revised:
24
05
2023
accepted:
02
07
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
This study evaluated the early, 1-year, and 3-year graft patency rates and mid-term clinical outcomes after no-touch saphenous veins (NT-SVs) were used as aortocoronary grafts in coronary artery bypass grafting (CABG). In total, 101 patients who underwent CABG using NT-SVs as aortocoronary grafts were included. The 2 most common indications for performing aortocoronary grafting with NT-SVs were unavailability of the left internal thoracic artery (n=36) and moderate lesions where flow competition was expected (n=27). Early (median, 1 day; interquartile range [IQR], 1-2 days), 1-year (median, 13 months; IQR, 11-16 months), and 3-year (median, 34 months; IQR, 27-41 months) graft angiography was performed in 98 (97.0%), 84 (83.2%), and 40 patients (39.6%), respectively. The median follow-up duration was 43 months (IQR, 13-76 months). Overall survival rates and the cumulative incidence of major adverse cardiac events were evaluated. The operative mortality rate was 2% (2 of 101 patients). Early postoperative patency rates for overall and aortocoronary NT-SV grafts were 98.2% (223 of 227 distal anastomoses) and 98.2% (164 of 167), respectively. The 1- and 3-year patency rates for aortocoronary SV grafts were 94.9% (131 of 138) and 90.6% (58 of 64), respectively. The overall survival rates at 5 and 10 years were 81.7% and 59%, respectively. The cumulative incidence of major adverse cardiac events at 5 and 10 postoperative years was 20.7% and 39%, respectively. The feasibility of using NT-SVs as aortocoronary grafts in CABG was shown in this study, based on the graft patency rates up to 3 years and the mid-term clinical outcomes.
Sections du résumé
Background
UNASSIGNED
This study evaluated the early, 1-year, and 3-year graft patency rates and mid-term clinical outcomes after no-touch saphenous veins (NT-SVs) were used as aortocoronary grafts in coronary artery bypass grafting (CABG).
Methods
UNASSIGNED
In total, 101 patients who underwent CABG using NT-SVs as aortocoronary grafts were included. The 2 most common indications for performing aortocoronary grafting with NT-SVs were unavailability of the left internal thoracic artery (n=36) and moderate lesions where flow competition was expected (n=27). Early (median, 1 day; interquartile range [IQR], 1-2 days), 1-year (median, 13 months; IQR, 11-16 months), and 3-year (median, 34 months; IQR, 27-41 months) graft angiography was performed in 98 (97.0%), 84 (83.2%), and 40 patients (39.6%), respectively. The median follow-up duration was 43 months (IQR, 13-76 months). Overall survival rates and the cumulative incidence of major adverse cardiac events were evaluated.
Results
UNASSIGNED
The operative mortality rate was 2% (2 of 101 patients). Early postoperative patency rates for overall and aortocoronary NT-SV grafts were 98.2% (223 of 227 distal anastomoses) and 98.2% (164 of 167), respectively. The 1- and 3-year patency rates for aortocoronary SV grafts were 94.9% (131 of 138) and 90.6% (58 of 64), respectively. The overall survival rates at 5 and 10 years were 81.7% and 59%, respectively. The cumulative incidence of major adverse cardiac events at 5 and 10 postoperative years was 20.7% and 39%, respectively.
Conclusion
UNASSIGNED
The feasibility of using NT-SVs as aortocoronary grafts in CABG was shown in this study, based on the graft patency rates up to 3 years and the mid-term clinical outcomes.
Identifiants
pubmed: 37574877
pii: jcs.23.027
doi: 10.5090/jcs.23.027
pmc: PMC10480399
doi:
Types de publication
Journal Article
Langues
eng
Pagination
313-321Références
Eur J Cardiothorac Surg. 2010 Oct;38(4):414-9
pubmed: 20362457
N Engl J Med. 1996 Jan 25;334(4):216-9
pubmed: 8531997
Ann Thorac Surg. 2011 Aug;92(2):579-85; discussion 585-6
pubmed: 21801913
Interact Cardiovasc Thorac Surg. 2022 Jul 9;35(2):
pubmed: 35426918
Ann Thorac Surg. 2017 May;103(5):1489-1497
pubmed: 27916241
Ann Thorac Surg. 2002 Apr;73(4):1189-95
pubmed: 11996262
Ann Cardiothorac Surg. 2018 Sep;7(5):686-689
pubmed: 30505754
Prog Cardiovasc Dis. 1991 Jul-Aug;34(1):45-68
pubmed: 2063013
J Chest Surg. 2022 Oct 5;55(5):378-387
pubmed: 35822442
Circulation. 1983 Sep;68(3 Pt 2):II1-7
pubmed: 6603280
J Thorac Cardiovasc Surg. 1994 Mar;107(3):707-16
pubmed: 8127100
J Thorac Cardiovasc Surg. 2006 Aug;132(2):373-8
pubmed: 16872965
J Chest Surg. 2021 Apr 05;54(2):117-126
pubmed: 33767015
Ann Thorac Surg. 2015 Jul;100(1):59-66
pubmed: 25886807
J Am Coll Cardiol. 2012 Jul 3;60(1):28-35
pubmed: 22742399
J Biomech. 2005 Sep;38(9):1760-9
pubmed: 16023463
J Thorac Cardiovasc Surg. 2021 Nov;162(5):1535-1543.e4
pubmed: 32418633
Scand Cardiovasc J. 1999;33(6):323-9
pubmed: 10622542
Tex Heart Inst J. 2000;27(4):346-9
pubmed: 11198306
Circulation. 2022 Jan 18;145(3):e18-e114
pubmed: 34882435
J Chest Surg. 2023 Mar 5;56(2):99-107
pubmed: 36792946
J Vasc Surg. 1988 Sep;8(3):316-20
pubmed: 3418831
Curr Control Trials Cardiovasc Med. 2005 Oct 11;6:15
pubmed: 16219100
Eur J Cardiothorac Surg. 2022 Jun 15;62(1):
pubmed: 35678560
Circulation. 2012 Sep 11;126(11 Suppl 1):S170-5
pubmed: 22965979
J Am Coll Cardiol. 2011 Dec 6;58(24):e123-210
pubmed: 22070836
N Engl J Med. 1986 Jan 2;314(1):1-6
pubmed: 3484393
J Korean Med Sci. 2019 Apr 08;34(13):e104
pubmed: 30950250
Ann Thorac Surg. 2001 Sep;72(3):S1033-7
pubmed: 11565721